{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:15:42Z","timestamp":1775682942915,"version":"3.50.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Pregabalin may reduce the quality of life due to oedema, which may lead to further adverse events if co-administered with diuretics. This study investigated the occurrence of oedema and loop diuretic prescriptions in Japanese patients treated with pregabalin, including the temporal characteristics of the onset and factors associated with oedema.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Japanese Adverse Drug Event Report database, we performed logistic regression analysis to calculate adjusted reporting odds ratios to assess the association between pregabalin and oedema, and time-of-onset analysis to identify the timing of oedema onset. Using the prescription claims database of the Japanese pharmacy group, we assessed the occurrence of loop diuretic prescriptions associated with pregabalin by calculating the adjusted sequence ratios in the prescription sequence symmetry analysis, and identified the associated factors in subgroup analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The adjusted reporting odds ratio was 6.89 (95% confidence interval: 5.96\u20137.91) for pregabalin, adjusted for age and sex as covariates. The median time to onset of oedema was 16.0 days (interquartile range: 6.0\u201342.0 days). The adjusted sequence ratio was 1.17 (95% confidence interval: 1.09\u20131.25), with subgroup analyses confirming a significant association at starting doses of 150 mg\/day and more.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests that oedema and loop diuretic prescriptions are associated with pregabalin use. Pregabalin-induced oedema was more common early in treatment and loop diuretics were more likely to be prescribed when the starting dose of pregabalin was 150 mg\/day or more.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijpp\/riaf012","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:52:21Z","timestamp":1744987941000},"page":"340-346","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of pregabalin-induced oedema using the adverse event spontaneous reporting database and the prescription claims database"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9155-2386","authenticated-orcid":false,"given":"Hitoshi","family":"Ito","sequence":"first","affiliation":[{"name":"AIN Holdings Inc. , Shibuya-ku, Tokyo 151-0053 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"AIN Holdings Inc. , Shibuya-ku, Tokyo 151-0053 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Maeda","sequence":"additional","affiliation":[{"name":"AIN Holdings Inc. , Shibuya-ku, Tokyo 151-0053 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Tsukioka","sequence":"additional","affiliation":[{"name":"AIN Holdings Inc. , Shibuya-ku, Tokyo 151-0053 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Teikyo University School of Medicine University Hospital, Teikyo University , Tokyo 173-8606 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Yasuno","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Teikyo University School of Medicine University Hospital, Teikyo University , Tokyo 173-8606 ,","place":["Japan"]},{"name":"Laboratory of Hospital Pharmacy, Faculty of Pharma Sciences, Teikyo University , Tokyo 173-8605 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miya","family":"Oishi","sequence":"additional","affiliation":[{"name":"AIN Holdings Inc. , Shibuya-ku, Tokyo 151-0053 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2025061002115663300_CIT0001","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur J Neurol"},{"key":"2025061002115663300_CIT0002","author":"National Institute for Health and Care Excellence (NICE)","year":"2020"},{"key":"2025061002115663300_CIT0003","author":"Viatris Inc","year":"2023"},{"key":"2025061002115663300_CIT0004","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00540-018-2501-0","article-title":"Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians","volume":"32","author":"Sumitani","year":"2018","journal-title":"J Anesth"},{"key":"2025061002115663300_CIT0005","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract"},{"key":"2025061002115663300_CIT0006","doi-asserted-by":"publisher","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials","volume":"9","author":"Onakpoya","year":"2019","journal-title":"BMJ Open"},{"key":"2025061002115663300_CIT0007","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.12998\/wjcc.v11.i17.4060","article-title":"Pregabalin induced balance disorder, asthenia, edema, and constipation in an elderly adult: a case report","volume":"11","author":"Ma","year":"2023","journal-title":"World J Clin Cases"},{"key":"2025061002115663300_CIT0008","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1111\/jgs.17312","article-title":"Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain","volume":"69","author":"Read","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"2025061002115663300_CIT0009","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025061002115663300_CIT0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00001648-199609000-00005","article-title":"Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis","volume":"7","author":"Hallas","year":"1996","journal-title":"Epidemiology"},{"key":"2025061002115663300_CIT0011","doi-asserted-by":"publisher","first-page":"17652","DOI":"10.1038\/s41598-022-22257-2","article-title":"Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database","volume":"12","author":"Yamashiro","year":"2022","journal-title":"Sci Rep"},{"key":"2025061002115663300_CIT0012","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database","volume":"2","author":"Abe","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"2025061002115663300_CIT0013","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","article-title":"The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection","volume":"22","author":"Wahab","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025061002115663300_CIT0014","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","article-title":"Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database","volume":"37","author":"Takada","year":"2014","journal-title":"Drug Saf"},{"key":"2025061002115663300_CIT0015","doi-asserted-by":"publisher","first-page":"e0172057","DOI":"10.1371\/journal.pone.0172057","article-title":"Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database","volume":"12","author":"Hosoya","year":"2017","journal-title":"PLoS One"},{"key":"2025061002115663300_CIT0016","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf"},{"key":"2025061002115663300_CIT0017","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/00001648-199710000-00009","article-title":"The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization","volume":"8","author":"Hallas","year":"1997","journal-title":"Epidemiology"},{"key":"2025061002115663300_CIT0018","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/ajh\/hpac013","article-title":"Evaluation of a beta-blocker-edema-loop diuretic prescribing cascade: a prescription sequence symmetry analysis","volume":"35","author":"Vouri","year":"2022","journal-title":"Am J Hypertens"},{"key":"2025061002115663300_CIT0019","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.3780","article-title":"Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries","volume":"24","author":"Pratt","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025061002115663300_CIT0020","doi-asserted-by":"publisher","first-page":"554899","DOI":"10.3389\/fpsyt.2020.554899","article-title":"A systematic review of efficacy, safety, and tolerability of duloxetine","volume":"11","author":"Rodrigues-Amorim","year":"2020","journal-title":"Front Psychiatry"},{"key":"2025061002115663300_CIT0021","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/TCRM.S204860","article-title":"Association of atorvastatin with the risk of hepatotoxicity: a pilot prescription sequence symmetry analysis","volume":"15","author":"Zhang","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2025061002115663300_CIT0022","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freynhagen","year":"2005","journal-title":"Pain"},{"key":"2025061002115663300_CIT0023","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11256\/jjdi.22.7","article-title":"Creating a checklist and a survey on research that used the Japanese Adverse Drug Event Report database","volume":"22","author":"Sakai","year":"2020","journal-title":"Jpn J Drug Inf"},{"key":"2025061002115663300_CIT0024","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2296-11-85","article-title":"Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies","volume":"11","author":"Semel","year":"2010","journal-title":"BMC Fam Pract"},{"key":"2025061002115663300_CIT0025","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12874-017-0457-7","article-title":"A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies","volume":"18","author":"Takeuchi","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025061002115663300_CIT0026","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"key":"2025061002115663300_CIT0027","doi-asserted-by":"publisher","first-page":"112807","DOI":"10.1016\/j.biopha.2022.112807","article-title":"Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments","volume":"149","author":"Largeau","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025061002115663300_CIT0028","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/jcph.1450","article-title":"Population pharmacokinetics of pregabalin extended-release in healthy volunteers and patients with postherpetic neuralgia, fibromyalgia, and partial-onset seizures","volume":"59","author":"Chew","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2025061002115663300_CIT0029","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12874-023-02108-y","article-title":"Prescription Sequence Symmetry Analysis (PSSA) to assess prescribing cascades: a step-by-step guide","volume":"24","author":"Hendrix","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"2025061002115663300_CIT0030","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/bcp.14752","article-title":"Drug-induced peripheral oedema: An aetiology-based review","volume":"87","author":"Largeau","year":"2021","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/33\/3\/340\/62953800\/riaf012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/33\/3\/340\/62953800\/riaf012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:12:02Z","timestamp":1749535922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/33\/3\/340\/8116078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,4,18]]},"published-print":{"date-parts":[[2025,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaf012","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,18]]}}}